Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

Tereshchenko S.N. ^{1, 2} , Shestakova M.V.³ , Ageev F.T.¹ , Galstyan G.R.³ , Galyavich A.S. ⁴ , Glezer M.G. ⁵ , Zhirov I.V.^{1, 2} , Karpov Y.A.¹ , Kobalava Z.D. ⁶ , Matskeplishvili S.T.⁷

Russian Journal of Cardiology

Silicea-Poligraf

5

Русский

114-120

Опубликовано

Внешняя ссылка

10.15829/1560-4071-2020-3919

3919

25

2020

• ¹ National Medical Research Center of Cardiology, Moscow, Russian Federation
• ² Russian Academy of Postgraduate Medical Education, Moscow, Russian Federation
• ³ National Medical Research Center for Endocrinology, Moscow, Russian Federation
• ⁴ Kazan State Medical University, Kazan, Russian Federation
• ⁵ I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
• ⁶ Peoples’ Friendship University of Russia, Moscow, Russian Federation
• ⁷ Medical Research and Educational Center, Moscow State University, Moscow, Russian Federation

DAPA-HF trial; Dapagliflozin; Heart failure with reduced ejection fraction